NeuroMetrix Inc
Change company Symbol lookup
Select an option...
NURO NeuroMetrix Inc
OTTW Ottawa Savings Bancorp Inc
HMC Honda Motor Co Ltd
PAVMZ PAVmed Series Z Equity Warrants Exp 30 Apr 2024 *W EXP 04/30/2024
FFBW Ffbw Inc
CIB Bancolombia SA
TARA Protara Therapeutics Inc
SLAMU Slam Corp
SY So-Young International Inc
BHR Braemar Hotels & Resorts Inc
Go

Health Care : Health Care Equipment & Supplies | Small Cap Value
Company profile

NeuroMetrix, Inc. develops and commercializes health care products that utilize non-invasive neurostimulation. The Company is engaged in the designing, building and marketing of medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. It has two principal product categories, which includes point-of-care neuropathy diagnostic tests and wearable neurostimulation devices. Its products include DPNCheck, Quell and ADVANCE System. DPNCheck is a quantitative nerve conduction test that is used to evaluate peripheral neuropathies, such as Diabetic peripheral neuropathy (DPN). Quell a wearable device for symptomatic relief and management of chronic pain. ADVANCE System is a platform for the performance of nerve conduction studies. DPNCheck customers include managed care organizations, endocrinologists, podiatrists and primary care physicians. ADVANCE System customers include occupational health, primary care, internal medicine and many others.

Closing Price
$3.64
Day's Change
-0.04 (-1.09%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.67
Day's Low
3.45
Volume
(Light)
Volume:
23,881

10-day average volume:
71,663
23,881

AFRM SHAREHOLDER ALERT: Jakubowitz Law Reminds Affirm Shareholders of a Lead Plaintiff Deadline of April 29, 2022

5:45 am ET April 29, 2022 (PR Newswire) Print

Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Affirm Holdings, Inc. (NASDAQ: AFRM).

To receive updates on the lawsuit, fill out the form:https://claimyourloss.com/securities/affirm-holdings-inc-loss-submission-form/?id=26463&from=4

The lawsuit seeks to recover losses for shareholders who purchased Affirm between February 12, 2021 and February 10, 2022.

Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until April 29, 2022 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

According to a filed complaint, Affirm Holdings, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (i) Affirm's "buy now, pay-later" service facilitated excessive consumer debt, regulatory arbitrage, and data harvesting; (ii) the foregoing subjected Affirm to a heightened risk of regulatory scrutiny and enforcement action; (iii) Affirm maintained inadequate disclosure controls and procedures and internal control over financial reporting; (iv) accordingly, Affirm's tweet for its second quarter 2022 financial results contained selected metrics that made it appear that the Company had performed better than it actually did; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: JAKUBOWITZ LAW 1140 Avenue of the Americas 9th Floor New York, New York 10036 T: (212) 867-4490 F: (212) 537-5887

https://c212.net/c/img/favicon.png?sn=NY40882&sd=2022-04-29

View original content:https://www.prnewswire.com/news-releases/afrm-shareholder-alert-jakubowitz-law-reminds-affirm-shareholders-of-a-lead-plaintiff-deadline-of-april-29-2022-301536045.html

SOURCE Jakubowitz Law

https://rt.prnewswire.com/rt.gif?NewsItemId=NY40882&Transmission_Id=202204290545PR_NEWS_USPR_____NY40882&DateId=20220429

comtex tracking

COMTEX_406426739/1005/2022-04-29T05:45:08

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.